- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04010253
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis (MUCOSIM)
July 20, 2022 updated by: Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Impact of Bronchial Drainage by the Medical Device Simeox® on Function and Respiratory Symptoms Compared to Manual Autogenous Drainage Physiotherapy in Adult Cystic Fibrosis Patients
The main objective of the study is to evaluate the short-term effects of the airway clearance technique by the medical device Simeox (Physio Assist, France) versus Autogenic Drainage, on the pulmonary function of adult patients with stable cystic fibrosis.
To analyse these effects, the investigators used forced oscillation technique measured by TremoFlo™ C-100 Airwave Oscillometry System™ (THORASYS Thoracic Medical Systems Inc.
Montreal, Quebec, Canada) with an evaluation of the perceived clinical benefits.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
42
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jacqueline DELRIEU, PhD
- Phone Number: 0156814060
- Email: delrieu@antadir.com
Study Locations
-
-
-
Amiens, France
- Recruiting
- CH Amiens
-
Contact:
- Claire POULET, MD
-
Dijon, France
- Recruiting
- Hôpital la Bocage CHRU de Dijon
-
Contact:
- Guillaume BELTRAMO, MD
-
Lille, France
- Recruiting
- CHRU Lille - Hopital Calmette
-
Contact:
- Thierry Perez, MD
- Email: thierry.perez@chru-lille.fr
-
Lyon, France
- Suspended
- GH Sud - Hospices Civils de Lyon
-
Nice, France
- Recruiting
- CH Nice
-
Roscoff, France
- Recruiting
- Soins de Suite Nutritionnels et Respiratoires -Fondation IDLYS
-
Contact:
- Thomas ROPARS, MD
-
Rouen, France
- Recruiting
- CHU de Rouen
-
Toulouse, France
- Recruiting
- Hopital Larrey
-
Contact:
- Marlène MURRIS-ESPIN, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of cystic fibrosis confirmed
- Age ≥18 years
- 30% <FEV1 <70% predicted
- Presence of bronchial congestion reported by the patient or the investigator
Exclusion Criteria:
- Uncontrolled asthma
- Pneumothorax <6 weeks
- Recent severe hemoptysis <6 weeks
- Patient registered on the transplant list
- Exacerbation within 4 weeks (3 months if hospitalization) before screening
- Cardiovascular disorders, electrocardiogram (ECG) parameters or clinically significant respiratory (non-cystic fibrosis) conditions
- Patients unable to perform measurements of ROF, spirometry, plethysmography.
- Any contraindication to manual or instrumental physiotherapy.
- Pregnancy, breastfeeding.
- Patient under tutorship or curatorship
- No affiliation to the French social security
- Patient using Simeox at home
- Patient under Trikafta for less than 6 weeks.
- Patient using Simeox more than twice a week during physiotherapy sessions, not wanting a washout period of 7 days before inclusion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: SIMEOX
|
Manual aiway clearance by autogenic drainage
|
ACTIVE_COMPARATOR: Autogenic Drainage
|
Instrumental airway clearance by the medical device SIMEOX
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Low frequency resistance R5
Time Frame: 1 month
|
Comparison of variations V4 and V8 sessions (pre and post airway clearance session)
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Comparison of the impact of Simeox® bronchial drainage compared to autogenous drainage on respiratory symptoms: dyspnea, congestion and fatigue
Time Frame: 1 month
|
1 month
|
Evaluation of the distal and / or proximal decluttering by the two techniques, according to the improvement profile of the forced oscillations
Time Frame: 1 month
|
1 month
|
Evaluation of the impact of Simeox® bronchial drainage vs autogenous drainage by spirometry and plethysmography (distension and resistance)
Time Frame: 1 month
|
1 month
|
Evaluation of correlations between clinical benefit and changes in functional respiratory investigations (forced oscillations, spirometry, plethysmography)
Time Frame: 1 month
|
1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 30, 2019
Primary Completion (ANTICIPATED)
December 30, 2023
Study Completion (ANTICIPATED)
December 31, 2023
Study Registration Dates
First Submitted
July 3, 2019
First Submitted That Met QC Criteria
July 5, 2019
First Posted (ACTUAL)
July 8, 2019
Study Record Updates
Last Update Posted (ACTUAL)
July 21, 2022
Last Update Submitted That Met QC Criteria
July 20, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-A00622-55
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University Hospital, BordeauxCompleted
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
Clinical Trials on Autogenic drainage
-
Cliniques universitaires Saint-Luc- Université...Recruiting
-
Cairo UniversityPrincess Nourah Bint Abdulrahman UniversityCompletedPostoperative ComplicationsEgypt
-
Cliniques universitaires Saint-Luc- Université...Completed
-
Cliniques universitaires Saint-Luc- Université...Unknown
-
Universidad San JorgeCystic Fibrosis FoundationCompletedCystic FibrosisSpain
-
Carmel Medical CenterRambam Health Care CampusUnknownBronchiectasisIsrael
-
Riphah International UniversityCompletedPneumonia ChildhoodPakistan
-
Cliniques universitaires Saint-Luc- Université...Unknown
-
Vrije Universiteit BrusselCompleted
-
Riphah International UniversityCompletedChronic Obstructive Pulmonary DiseasePakistan